NasdaqGS:TEMLife Sciences
Record 2025 Revenue and New Cancer Data Deals Might Change The Case For Investing In Tempus AI (TEM)
In the past few days, Tempus AI reported preliminary 2025 results showing roughly US$1.27 billion in revenue with very large year-over-year growth, a record total contract value above US$1.10 billion, and more than 70 data agreements alongside new oncology collaborations with NYU Langone Health and Northwestern Medicine.
Together, these updates point to a company deepening its role at the intersection of genomic testing, longitudinal cancer data, and AI-powered decision support for both...